« Back
Home /
Luxdegalutamide

Luxdegalutamide

Item no.	HY-153342-100mg
Manufacturer	MedChem Express
CASRN	2750830-09-0
Amount	100 mg
Quantity options	100 mg 10 mg 1 ea 1 mg 25 mg 50 mg 5 mg
Specific against	other
Purity	98.94
Citations	[1]Petrylak D P, et al. A phase 2 expansion study of ARV-766, a PROTAC androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC)[J]. 2023.
Smiles	CC(C)([C@@H](C1(C)C)NC(C2=CC=C(N3CCC(CC3)CN4CCN(C5=CC(F)=C(C=C5)C(N[C@@H]6C(NC(CC6)=O)=O)=O)CC4)C=C2)=O)[C@@H]1OC7=CC(OC)=C(C=C7)C#N
Alias	ARV-766
Available
Product Description	Luxdegalutamide (ARV-766) is an orally active and potent proteolysis targeting chimera (PROTAC) protein degrader. Luxdegalutamide degrades wild-type androgen receptor (AR) but also relevant AR LBD mutants, including the most prevalent AR L702H, H875Y, and T878A mutations[1].
StorageTemperature	4°C (Powder, sealed storage, away from moisture)
Shipping	Room Temperature
Manufacturers Applications	Cancer-programmed cell death
MolecularWeight	807.95
Clinical Information	Phase 2
Manufacturers Research Area	Cancer
Solubility	DMSO : 100 mg/mL (ultrasonic)
Target	Androgen Receptor; PROTACs
Manufacturers Target	Androgen Receptor; PROTACs
Manufacturers Pathway	PROTAC; Vitamin D Related/Nuclear Receptor
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 100 mg

available

Request delivery time